This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Purnell, J. Q. Articles by Brunzell, J. D. Search for Related Content PubMed PubMed Citation Articles by Purnell, J. Q. Articles by Brunzell, J. D. Related Collections Lipids Obesity Glucose intolerance CT and MRI Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:567.)
© 2001 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Relationship of Insulin Sensitivity and ApoB Levels to Intra-abdominal Fat in Subjects With Familial Combined Hyperlipidemia

Jonathan Q. Purnell; Steven E. Kahn; Robert S. Schwartz; John D. Brunzell

From the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington (J.Q.P., J.D.B.), and the Seattle VA Puget Sound Health Care System (S.E.K.), Seattle, Wash, and the Department of Gerontology and Geriatric Medicine, University of Colorado (R.S.S.), Denver.

Correspondence to Jonathan Q. Purnell, MD, Oregon Health Sciences University, Division of Endocrinology, Diabetes, and Clinical Nutrition, Mailbox L607, 3181 SW Sam Jackson Park Rd, Portland, OR 97201. E-mail purnellj{at}ohsu.edu

Abstract—Familial combined hyperlipidemia (FCHL) is one of the most common familial dyslipidemias associated with premature heart disease. Subjects with FCHL typically have elevated apolipoprotein B (apoB) levels, variable elevations in cholesterol and/or triglycerides, and a predominance of small, dense, low density lipoprotein particles. It is thought that insulin resistance is important in the expression of the combined hyperlipidemia phenotype. To further characterize the relationship between insulin resistance and increased apoB levels, 11 subjects from well-characterized FCHL families and normal control subjects matched for weight and/or age underwent measurement of intra-abdominal fat (IAF) and subcutaneous fat (SQF) by CT scan, insulin sensitivity (Si) by the frequently sampled intravenous glucose tolerance test, and lipoprotein levels. Body mass index and IAF were higher and Si was lower (more insulin resistant) in the FCHL group than in the age-matched group, but the values were similar in the FCHL group and the age- and weight-matched control group. When the relationship between body fat distribution and Si was tested with multiple linear regression, only IAF was significantly correlated with Si after the addition of SQF and body mass index as independent variables. For any level of insulin sensitivity or IAF, however, apoB levels remained higher in the FCHL subjects than in the control groups. In conclusion, in FCHL, visceral obesity is an important determinant of insulin resistance. Visceral obesity and insulin resistance, however, do not fully account for the elevated levels of apoB in this disorder, and this study provides physiological support for separate, but additive, genetic determinants in the etiology of the lipid phenotype.

Key Words: obesity • insulin resistance • hyperlipidemia • visceral fat • apolipoproteins

This article has been cited by other articles:

				M De Michele, A Iannuzzi, A Salvato, P Pauciullo, M Gentile, G Iannuzzo, S Panico, A Pujia, G M Bond, and P Rubba Impaired endothelium-dependent vascular reactivity in patients with familial combined hyperlipidaemia Heart, January 1, 2007; 93(1): 78 - 81. [Abstract] [Full Text] [PDF]

				G. M Reaven The metabolic syndrome: is this diagnosis necessary? Am. J. Clinical Nutrition, June 1, 2006; 83(6): 1237 - 1247. [Abstract] [Full Text] [PDF]

				G. Reaven All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals Diabetes and Vascular Disease Research, October 1, 2005; 2(3): 105 - 112. [Abstract] [PDF]

				M.J. Veerkamp, J. de Graaf, and A.F.H. Stalenhoef Role of Insulin Resistance in Familial Combined Hyperlipidemia Arterioscler Thromb Vasc Biol, May 1, 2005; 25(5): 1026 - 1031. [Abstract] [Full Text] [PDF]

				M. C. Carr and J. D. Brunzell Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2601 - 2607. [Abstract] [Full Text] [PDF]

				A.M. Georgieva, M.M.J. van Greevenbroek, R.M. Krauss, M.C.G.J. Brouwers, V.M.M.-J. Vermeulen, M.G. Robertus-Teunissen, C.J.H. van der Kallen, and T.W.A. de Bruin Subclasses of Low-Density Lipoprotein and Very Low-Density Lipoprotein in Familial Combined Hyperlipidemia: Relationship to Multiple Lipoprotein Phenotype Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 744 - 749. [Abstract] [Full Text] [PDF]

				T. Ueno, J. Tremblay, J. Kunes, J. Zicha, Z. Dobesova, Z. Pausova, A. Y. Deng, Y.-L. Sun, H. J. Jacob, and P. Hamet Rat model of familial combined hyperlipidemia as a result of comparative mapping Physiol Genomics, March 12, 2004; 17(1): 38 - 47. [Abstract] [Full Text] [PDF]

				C. Verseyden, S. Meijssen, H. van Dijk, H. Jansen, and M. C. Cabezas Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia J. Lipid Res., November 1, 2003; 44(11): 2100 - 2108. [Abstract] [Full Text] [PDF]

				R. P. Naoumova, S. A. Bonney, S. Eichenbaum-Voline, H. N. Patel, B. Jones, E. L. Jones, J. Amey, S. Colilla, C. K.Y. Neuwirth, R. Allotey, et al. Confirmed Locus on Chromosome 11p and Candidate Loci on 6q and 8p for the Triglyceride and Cholesterol Traits of Combined Hyperlipidemia Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 2070 - 2077. [Abstract] [Full Text] [PDF]

				C.J.M. Halkes, H. van Dijk, C. Verseyden, P.P.Th. de Jaegere, H.W.M Plokker, S. Meijssen, D.W. Erkelens, and M. C. Cabezas Gender Differences in Postprandial Ketone Bodies in Normolipidemic Subjects and in Untreated Patients With Familial Combined Hyperlipidemia Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1875 - 1880. [Abstract] [Full Text] [PDF]

				P. N. Hopkins, G. Heiss, R. C. Ellison, M. A. Province, J. S. Pankow, J. H. Eckfeldt, and S. C. Hunt Coronary Artery Disease Risk in Familial Combined Hyperlipidemia and Familial Hypertriglyceridemia: A Case-Control Comparison From the National Heart, Lung, and Blood Institute Family Heart Study Circulation, August 5, 2003; 108(5): 519 - 523. [Abstract] [Full Text] [PDF]

				A. F. Ayyobi, S. H. McGladdery, M. J. McNeely, M. A. Austin, A. G. Motulsky, and J. D. Brunzell Small, Dense LDL and Elevated Apolipoprotein B Are the Common Characteristics for the Three Major Lipid Phenotypes of Familial Combined Hyperlipidemia Arterioscler Thromb Vasc Biol, July 1, 2003; 23(7): 1289 - 1294. [Abstract] [Full Text] [PDF]

				P. M. H. Eurlings, C. J. H. van der Kallen, J. M. W. Geurts, P. Kouwenberg, W. D. Boeckx, and T. W. A. de Bruin Identification of differentially expressed genes in subcutaneous adipose tissue from subjects with familial combined hyperlipidemia J. Lipid Res., June 1, 2002; 43(6): 930 - 935. [Abstract] [Full Text] [PDF]

				J. Vakkilainen, M. Jauhiainen, K. Ylitalo, I. O. Nuotio, J. S. A. Viikari, C. Ehnholm, and M.-R. Taskinen LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins J. Lipid Res., April 1, 2002; 43(4): 598 - 603. [Abstract] [Full Text] [PDF]